176 related articles for article (PubMed ID: 10965989)
1. HMG-CoA reductase activity in human liver microsomes: comparative inhibition by statins.
Dansette PM; Jaoen M; Pons C
Exp Toxicol Pathol; 2000 May; 52(2):145-8. PubMed ID: 10965989
[TBL] [Abstract][Full Text] [Related]
2. Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations.
Prueksaritanont T; Ma B; Tang C; Meng Y; Assang C; Lu P; Reider PJ; Lin JH; Baillie TA
Br J Clin Pharmacol; 1999 Mar; 47(3):291-8. PubMed ID: 10215754
[TBL] [Abstract][Full Text] [Related]
3. Pravastatin inhibited the cholesterol synthesis in human hepatoma cell line Hep G2 less than simvastatin and lovastatin, which is reflected in the upregulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and squalene synthase.
Cohen LH; van Vliet A; Roodenburg L; Jansen LM; Griffioen M
Biochem Pharmacol; 1993 Jun; 45(11):2203-8. PubMed ID: 8517861
[TBL] [Abstract][Full Text] [Related]
4. Atorvastatin action involves diminished recovery of hepatic HMG-CoA reductase activity.
Ness GC; Chambers CM; Lopez D
J Lipid Res; 1998 Jan; 39(1):75-84. PubMed ID: 9469588
[TBL] [Abstract][Full Text] [Related]
5. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors.
Transon C; Leemann T; Dayer P
Eur J Clin Pharmacol; 1996; 50(3):209-15. PubMed ID: 8737761
[TBL] [Abstract][Full Text] [Related]
6. Hep-G2 cells and primary rat hepatocytes differ in their response to inhibitors of HMG-CoA reductase.
Shaw MK; Newton RS; Sliskovic DR; Roth BD; Ferguson E; Krause BR
Biochem Biophys Res Commun; 1990 Jul; 170(2):726-34. PubMed ID: 2166504
[TBL] [Abstract][Full Text] [Related]
7. Tissue-selective acute effects of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase on cholesterol biosynthesis in lens.
Mosley ST; Kalinowski SS; Schafer BL; Tanaka RD
J Lipid Res; 1989 Sep; 30(9):1411-20. PubMed ID: 2513368
[TBL] [Abstract][Full Text] [Related]
8. Lipophilic HMG-CoA reductase inhibitors increase myocardial stunning in dogs.
Satoh K; Ichihara K
J Cardiovasc Pharmacol; 2000 Feb; 35(2):256-62. PubMed ID: 10672858
[TBL] [Abstract][Full Text] [Related]
9. Atorvastatin and simvastatin have distinct effects on hydroxy methylglutaryl-CoA reductase activity and mRNA abundance in the guinea pig.
Conde K; Roy S; Freake HC; Newton RS; Fernandez ML
Lipids; 1999 Dec; 34(12):1327-32. PubMed ID: 10652993
[TBL] [Abstract][Full Text] [Related]
10. Regulation of cytochrome P450 expression by inhibitors of hydroxymethylglutaryl-coenzyme A reductase in primary cultured rat hepatocytes and in rat liver.
Kocarek TA; Reddy AB
Drug Metab Dispos; 1996 Nov; 24(11):1197-204. PubMed ID: 8937853
[TBL] [Abstract][Full Text] [Related]
11. New insights into the pharmacodynamic and pharmacokinetic properties of statins.
Corsini A; Bellosta S; Baetta R; Fumagalli R; Paoletti R; Bernini F
Pharmacol Ther; 1999 Dec; 84(3):413-28. PubMed ID: 10665838
[TBL] [Abstract][Full Text] [Related]
12. Proapoptotic effect of atorvastatin on stimulated rabbit smooth muscle cells.
Baetta R; Donetti E; Comparato C; Calore M; Rossi A; Teruzzi C; Paoletti R; Fumagalli R; Soma MR
Pharmacol Res; 1997 Aug; 36(2):115-21. PubMed ID: 9344639
[TBL] [Abstract][Full Text] [Related]
13. Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase.
Corsini A; Mazzotti M; Raiteri M; Soma MR; Gabbiani G; Fumagalli R; Paoletti R
Atherosclerosis; 1993 Jun; 101(1):117-25. PubMed ID: 8216498
[TBL] [Abstract][Full Text] [Related]
14. [Cardiovascular pharmacology (VIII). The role of HMG CoA reductase inhibitors in the current treatment of hyperlipidemias].
Carmena R
Rev Esp Cardiol; 1995 Jan; 48(1):59-65. PubMed ID: 7878284
[No Abstract] [Full Text] [Related]
15. Fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase, scavenges free radicals and inhibits lipid peroxidation in rat liver microsomes.
Yamamoto A; Hoshi K; Ichihara K
Eur J Pharmacol; 1998 Nov; 361(1):143-9. PubMed ID: 9851551
[TBL] [Abstract][Full Text] [Related]
16. HMG CoA reductase inhibitors. In vivo effects on carotid intimal thickening in normocholesterolemic rabbits.
Soma MR; Donetti E; Parolini C; Mazzini G; Ferrari C; Fumagalli R; Paoletti R
Arterioscler Thromb; 1993 Apr; 13(4):571-8. PubMed ID: 8466892
[TBL] [Abstract][Full Text] [Related]
17. Selective inhibition of cholesterol synthesis in liver versus extrahepatic tissues by HMG-CoA reductase inhibitors.
Parker RA; Clark RW; Sit SY; Lanier TL; Grosso RA; Wright JJ
J Lipid Res; 1990 Jul; 31(7):1271-82. PubMed ID: 2401858
[TBL] [Abstract][Full Text] [Related]
18. [Statins: similarities and differences in the pharmacological, clinical and laboratory aspects].
Motti C; Gnasso A; Cortese C
Ann Ital Med Int; 2000; 15(1):96-102. PubMed ID: 10842898
[TBL] [Abstract][Full Text] [Related]
19. Effects of propionic acid and pravastatin on HMG-CoA reductase activity in relation to forestomach lesions in the rat.
Bueld JE; Bannenberg G; Netter KJ
Pharmacol Toxicol; 1996 Apr; 78(4):229-34. PubMed ID: 8861780
[TBL] [Abstract][Full Text] [Related]
20. Hepatic responses to inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase: a comparison of atorvastatin and simvastatin.
Bergstrom JD; Bostedor RG; Rew DJ; Geissler WM; Wright SD; Chao YS
Biochim Biophys Acta; 1998 Jan; 1389(3):213-21. PubMed ID: 9512650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
